Background: Cutaneous mastocytosis (CM) is a common type of mastocytosis. Current treatment of CM is generally symptomatic. Pimecrolimus has been demonstrated as an effective anti-inflammatory drug for the treatment of inflammatory skin diseases, but whether it treats CM remains unknown.
Methods: The murine model of CM was induced by subcutaneous injection of 100 μg/kg recombinant murine stem cell factor (rmSCF) for a total of 17 days in Balb/c mice. Beginning on the 8th day, treatment with pimecrolimus 1% cream or vehicle was performed topically and daily for 10 days. The clinical signs of CM were scored, and pathological analysis was performed with toluidine blue staining and hematoxylin and eosin staining. The in situ apoptotic mast cells (MCs) were studied by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay. The cutaneous histamine level was measured by ELISA.
Results: In the rmSCF-treated mice, the clinical signs of CM, including erythema, wheal after rubbing lesion skins, and increased thickness of skin, were obvious compared to control mice, and were reduced after pimecrolimus treatment. The numbers of cutaneous MCs and neutrophils were significantly greater in mice with CM than in control mice, and pimecrolimus treatment decreased the numbers of MCs but not neutrophils. Extensive apoptosis of cutaneous MCs was observed in pimecrolimus-treated mice. The cutaneous histamine level was elevated in the mice with CM compared with healthy controls, and was lowered after treatment with pimecrolimus.
Conclusions: Pimecrolimus effectively treats CM by reducing the density of cutaneous MCs and the subsequent histamine production through inducing MCs apoptosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000316353 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk Factors for Post Laryngectomy Pharyngocutaneous Fistula and Impact of Pharyngeal Suture Type on Fistula Characteristics.
Iran J Otorhinolaryngol
January 2025
Otolaryngology Department, San Antonio Catholic University of Murcia. Murcia, Spain.
Introduction: Pharyngocutaneous fistula (PCF) is the most common complication following total laryngectomy (TL). The factors contributing to its occurrence are still a matter of debate. The impact of suture type has been relatively underexplored.
View Article and Find Full Text PDFThe development of murine bone marrow-derived mast cells expressing functional human MRGPRX2 for and studies.
Front Immunol
January 2025
Department of Basic and Translational Sciences, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Introduction: A subtype of human mast cells (MCs) found in the skin and to a lesser extent in the lung and gut express a novel G protein-coupled receptor (GPCR) known as Mas-related GPCR-X2 (MRGPRX2, mouse counterpart MrgprB2). In addition to drug-induced pseudoallergy and cutaneous disorders, MrgprB2 contributes to ulcerative colitis, IgE-mediated lung inflammation and systemic anaphylaxis. Interestingly, most agonists activate MRGPRX2 with higher potency than MrgprB2.
View Article and Find Full Text PDFHistone acetylation alteration by KAT6A inhibitor WM-1119 suppresses IgE-mediated mast cell activation and allergic inflammation via reduction in AP-1 signaling.
Biochem Pharmacol
December 2024
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shenzhen University Medical School, Shenzhen University, Shenzhen 518055, China. Electronic address:
Activation of immunoglobulin E (IgE)-associated mast cells (MCs) triggers the onset of pro-inflammatory signals associated with type I allergic diseases. Although histone acetylation changes have been associated with inflammatory diseases, the impact of lysine-acetyltransferase (KAT) inhibitors on IgE-mediated MCs function is unclear. Potential anti-allergic effects of the KAT6A inhibitor WM-1119 on IgE-mediated MCs activation and allergic inflammation were examined in this study.
View Article and Find Full Text PDFMast cell sarcoma with KIT p.D816V mutation and concurrent systemic mastocytosis.
J Hematop
December 2024
Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, USA.
Mast cell sarcoma (MCS) is an extremely rare and aggressive form of mastocytosis characterized by highly atypical mast cells with local invasion, metastatic potential, and poor prognosis. MCS is predominantly a de novo process without recurrent molecular findings or predisposing lesions including various myeloid neoplasms. However, there have been rare case reports of MCS with preceding or concurrent systemic mastocytosis (SM) or cutaneous mastocytosis (CM), which is suggestive of an uncommon progression from SM/CM to MCS.
View Article and Find Full Text PDFA development of a gelatin and sodium carboxymethyl cellulose hydrogel system for dual-release transdermal delivery of lidocaine hydrochloride.
Int J Biol Macromol
January 2025
Department of Polymer Engineering, Faculty of Engineering, South Tehran Branch, Islamic Azad University, Po. Box: 11365/4435, Tehran, Iran; Nanotechnology Research Centre, Tehran South Branch, Islamic Azad University, Tehran, 15847-43311, Iran.
This study introduces a dual-release transdermal drug delivery system using a hydrogel matrix of cross-linked gelatin and sodium carboxymethyl cellulose (NaCMC). Designed for immediate drug release from microneedles (MNs) and sustained release from microcapsules (MCs), this system utilizes lidocaine hydrochloride as the model drug. The fabrication process involved casting the hydrogel into MN molds, with MCs embedded in the backing layer, establishing a dual-release mechanism.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!